Pharmaceutical Accountability Foundation meets AbbVie in court, looking to advance its pricing case

“The value of a human life is infinite, but unfortunately our healthcare budget is not,” said former Dutch Health Minister Bruno Bruins, quoted by...

It is not too late to solve the know-how problem in the WHO Pandemic...

Introduction One of the most important Intellectual Property (IP) problems which the Pandemic Accord negotiators need to solve is now in danger of being completely...

ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero Draft of the...

These remarks were delivered on the occasion of the fourth meeting of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement...

Wrapping up 2023 with some noteworthy medicines, law and policy developments

Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...

Wrapping up 2020 with some noteworthy medicines, law and policy events

Wrapping up the year 2020 can’t happen soon enough. This year, one way or the other, most people on the planet have been affected...

Remdesivir developed country price announced

On 29, June 2020 Gilead announced its global price for developed countries for remdesivir, a medicine that has shown some effect in the treatment...
Generic lumacaftor/ivacaftor

Cystic Fibrosis Buyers Club Shows the UK Government The Way

The move by a group of parents of children with cystic fibrosis (CF) to set up a buyers club to gain access to treatments...

Medicines Law & Policy’s director, Ellen ’t Hoen, receives high Netherlands honour for her...

Ellen 't Hoen has been appointed Officer of the Order of Oranje-Nassau, a royal award which recognises those who merit particular appreciation from society...

Dutch Court Orders AstraZeneca to Pay Damages in Patent Evergreening Case

Today the Dutch court made a long-awaited ruling in the patent evergreening case of health insurance company Menzis versus AstraZeneca. It found that AstraZeneca...

Something is going terribly wrong with the EU Compulsory Licensing Regulation

This week the European Parliament will vote on amendments to the Commission’s proposed regulation of the European Parliament and the Council on compulsory licensing...